<DOC>
	<DOC>NCT02062684</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of subcutaneous blisibimod administration in addition to standard therapy in patients with biopsy proven IgA Nephropathy with persistent proteinuria of between 1-6 g/day.</brief_summary>
	<brief_title>BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis, IGA</mesh_term>
	<criteria>18 65 years of age, inclusive Biopsyproven IgA nephropathy Receiving stable, clinicallyoptimized ACEI and/or ARB Proteinuria ≥ 1g/24hr but ≤ 6g/24hr at 2 consecutive time points Clinical or histologic evidence of nonIgArelated glomerulonephritis IgA nephropathy with greater than 50% glomerulosclerosis or cortical scarring Meets eGFR criteria History of treatment with oral or parenteral corticosteroids within 3 months or immunosuppressants within 6 months Malignancy within past 5 years Known to be positive for HIV and/or positive at the screening visit for hepatitis B, or hepatitis C Liver disease Neutropenia Active infection requiring hospitalization or treatment with parenteral antibiotics within the past 60 days or history of repeated herpetic viral infections History of active tuberculosis or a history of tuberculosis infection Pregnant or nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>IgAN</keyword>
	<keyword>IgA Nephropathy</keyword>
	<keyword>A-623</keyword>
	<keyword>Blisibimod</keyword>
	<keyword>Kidney Disease</keyword>
	<keyword>Persistent proteinuria</keyword>
</DOC>